argenx SE (ARGX) News

argenx SE (ARGX)

Today's Latest Price: $248.13 USD

6.25 (-2.46%)

Updated Oct 30 4:00pm

Add ARGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

Filter ARGX News Items

ARGX News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ARGX News From Around the Web

Below are the latest news stories about Argenx Se that investors may wish to consider to help them evaluate ARGX as an investment opportunity.

J&J takeout of Momenta lifts argenx SE

Thinly traded argenx SE (ARGX) perks up 1% premarket on light volume on the heels of Johnson & Johnson's (JNJ) $6.5B takeout of Momenta Pharmaceuticals (MNTA).The Belgian biotech's antibody engineering technology is similar to Momenta's, both involving the Fc region where antibodies modulate other cells in the immune system.In May, argenx reported...

Seeking Alpha | August 19, 2020

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

argenx SE (ARGX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Keith Woods - Chief Operating Officer Eric Castaldi - Chief Financial Officer Conference Call Participants Yaron Werber - Cowen Yatin...

SA Transcripts on Seeking Alpha | August 2, 2020

argenx SE 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by argenx SE in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 1, 2020

Argenx SE reports 1H results

Argenx SE (ARGX): 1H net loss of €205.6MRevenue of €22.39M (-48.6% Y/Y)Press Release...

Seeking Alpha | July 30, 2020

argenx reports half year 2020 financial results and provides second quarter business update

* Biologics License Application for efgartigimod in generalized myasthenia gravis on track to be submitted to U.S. Food and Drug Administration by end of year * Full data from ADAPT trial to be presented at upcoming medical meeting in 2020 * Cusatuzumab development strategy aligned with evolving AML treatment landscape to focus on combination with venetoclax and azacitidine * €1.9 billion in cash and cash equivalents and current financial assets strongly support commercial launch preparation of efgartigimod * Management to host conference call today at 2:30 pm CEST (8:30 am ET) July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune disease...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On argenx SE (ARGX) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 20, 2020

argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | July 1, 2020

Is argenx SE (ARGX) A Good Stock To Buy?

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 15, 2020

argenx announces closing of global offering

Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 548,777 additional ADSs. Stifel, JMP Securities, Wedbush PacGrow, Nomura and Kempen & Co acted as co-managers for the offering. The securities were offered in the United States pursuant to an automatically effective shelf registration statement that was previously filed with the Se...

Yahoo | June 1, 2020

argenx announces full exercise of underwriters’ option to purchase additional ADSs

Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 548,777 additional ADSs in full on the same terms and conditions as the global offering. This option exercise brings the anticipated total gross proceeds from the global offering to approximately $862.5 million (approximately €784.7 million) from the sale of an aggregate of 4,207,292 ordinary shares (including ordinary shares repre...

Yahoo | May 29, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4601 seconds.